Clinical Trials Logo

Mood Disorders clinical trials

View clinical trials related to Mood Disorders.

Filter by:

NCT ID: NCT04298944 Completed - Hypertension Clinical Trials

Association of Mood With Risk for Atherosclerosis

AuRA
Start date: March 11, 2020
Phase:
Study type: Observational [Patient Registry]

The investigators will aim to determine the association of mood disorders (MDO) with preclinical and clinical cardiovascular (CVD) risk factors among children. The investigators will also aim to identify traditional and non traditional predictors of CVD risk among children with MDO.

NCT ID: NCT04289740 Recruiting - Emotional Disorder Clinical Trials

Transdiagnostic Group Cognitive Behavioral Therapy (PsicAP-A) for Adolescents With Emotional Disorders

PsicAP-A
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Emotional disorders such as anxiety and depression are highly prevalent during adolescence and associated with functional impairment that commonly extends into adulthood. In the primary care (PC) setting, these disorders are frequently underdiagnosed and undertreated. Objective: To carry out a prospective, randomized controlled trial (RCT) to test the efficacy of a new transdiagnostic cognitive behavioural group therapy (TD-CBT) protocol for adolescents (age 12 to 18 years) compared to group relaxation therapy (RT). Methods: Two-arm, single-blind, RCT (expected N=160) to compare group TD-CBT for emotional disorders to group RT. The group TD-CBT will be administered in seven sessions (90 min/session) over 12 weeks. Psychological assessments will be carried out at baseline, post-treatment, and at months 3, 6, and 12 after treatment. The assessments will include measures of depression, anxiety, somatization, quality of life, disability, and cognitive-emotional factors. The study will be conducted in two PC centres located in Cantabria, Spain. Discussion: This is the first RCT to evaluate the efficacy of group TD-CBT for emotional disorders in adolescents in the PC setting in Spain. If, as expected, the results confirm the superiority of TD-CBT to conventional RT, the widespread implementation of this new approach-based on scientific evidence obtained in a real-world, primary care setting-could improve treatment outcomes and quality of life in adolescents suffering from anxiety or depression.

NCT ID: NCT04288609 Not yet recruiting - Affective Disorder Clinical Trials

Effectiveness of a Cognitive Remediation Intervention Based on Virtual Reality for Promotion of Cognitive Functioning and Participation in Daily Life Among Persons With Affective Disorder

Start date: March 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to test the efficacy of remedial cognitive intervention using The Functional Brain Trainer VR (FBT, Intendo ©) to improve cognitive functioning, participation in daily life occupations, and functional capacity in the field of IADL among people with affective disorders receiving inpatient and daycare mental-health services.

NCT ID: NCT04284267 Recruiting - Bipolar Disorder Clinical Trials

Neuromodulation for Enhancement of Emotion Regulation in Bipolar Mood Disorders

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The investigators are conducting this research study to better understand how individuals with bipolar disorder regulate their emotions, and if transcranial magnetic stimulation (TMS) can help improve emotion regulation for individuals with bipolar mood disorders.

NCT ID: NCT04268303 Completed - Schizophrenia Clinical Trials

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

SERENITY I
Start date: January 24, 2020
Phase: Phase 3
Study type: Interventional

This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with schizophrenia, schizoaffective disorder or schizophreniform disorder.

NCT ID: NCT04251000 Completed - Clinical trials for Seasonal Affective Disorder

Infrared Photomodulation Therapy for Seasonal Affective Disorder

Start date: February 27, 2020
Phase: N/A
Study type: Interventional

During winter months in northern latitudes use of Joovv device on self-reported non-clinical mental health (aka mood), sleep and energy levels. Participants will also submit Withings and Oura activity and sleep data.

NCT ID: NCT04242550 Completed - Anxiety Disorders Clinical Trials

Binge Eating Anxiety and Mood

BEAM
Start date: June 23, 2020
Phase: N/A
Study type: Interventional

Binge Eating Disorder (BED) is the most common eating disorder, and currently, the best behavioral treatments only work for 40-60% of adults. BED often co-occurs with mood and anxiety disorders, and both are associated with neurocognitive deficits related to executive function (EF). These EF deficits contribute to worsening BED symptoms and make it difficult for these adults to adhere to treatment recommendations. The proposed study aims to develop an EF training enhanced behavioral treatment for BED and compare its effectiveness to the standard cognitive behavioral therapy for patients with BED and a co-occurring mood or anxiety disorder.

NCT ID: NCT04232267 Completed - Sleep Disorder Clinical Trials

Analysis of Sleep Study Data to Assess Depressive Burden

SADB
Start date: January 13, 2020
Phase:
Study type: Observational

This study evaluates the effectiveness of the MEB-001 device in assessing physiological parameters that provide a clinically significant depressive burden screener. This study uses objective physiological markers from MEB-001 to estimate the clinically significant depressive burden as subjectively reported by the subject with the Beck Depression Inventory - II (BDI-II).

NCT ID: NCT04226963 Completed - Clinical trials for Major Depressive Disorder

A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders

GDKet
Start date: December 4, 2019
Phase:
Study type: Observational [Patient Registry]

This study aims to openly test the long-term safety, tolerability and effectiveness of repeated administration of IV, nasal spray and oral ketamine for treatment-resistant mood disorders.

NCT ID: NCT04222816 Completed - Clinical trials for Bipolar Affective Disorder

Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder

Start date: January 16, 2020
Phase: Phase 4
Study type: Interventional

Bipolar affective disorder or manic -depressive psychosis (MDP) is a mood disorder affecting 2.4% of the global population . Lithium is considered as the "gold standard" for the treatment of bipolar disorder but the clinical use of lithium is often restricted due to its narrow therapeutic range and adverse effects. In a published case report, Bleiwiss H found that sodium chloride supplementation diminished the adverse effects caused by lithium The literature search also revealed that till date, there is no published clinical study evaluating the effect of dietary intake of sodium in preventing the fluctuations of serum lithium level and lithium toxicity Therefore, a randomized clinical trial has been designed to evaluate the effect of regulated add -on dietary sodium chloride on serum lithium levels in bipolar disorder.